These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 25998996)

  • 1. Transarterial chemoembolization for hepatocellular carcinoma: An old method, now flavor of the day.
    Boulin M; Delhom E; Pierredon-Foulongne MA; Cercueil JP; Guiu B
    Diagn Interv Imaging; 2015 Jun; 96(6):607-15. PubMed ID: 25998996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion.
    de Baere T; Arai Y; Lencioni R; Geschwind JF; Rilling W; Salem R; Matsui O; Soulen MC
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):334-43. PubMed ID: 26390875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model.
    Qian J; Oppermann E; Tran A; Imlau U; Qian K; Vogl TJ
    World J Gastroenterol; 2016 Jun; 22(21):5042-9. PubMed ID: 27275096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease.
    Fidelman N; Kerlan RK
    AJR Am J Roentgenol; 2015 Oct; 205(4):742-52. PubMed ID: 26397322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
    Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.
    Casadaban LC; Minocha J; Bui JT; Knuttinen MG; Ray CE; Gaba RC
    AJR Am J Roentgenol; 2016 Mar; 206(3):645-54. PubMed ID: 26901023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review.
    Horikawa M; Miyayama S; Irie T; Kaji T; Arai Y
    AJR Am J Roentgenol; 2015 Oct; 205(4):764-73. PubMed ID: 26397324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.
    Takayasu K; Arii S; Kudo M; Ichida T; Matsui O; Izumi N; Matsuyama Y; Sakamoto M; Nakashima O; Ku Y; Kokudo N; Makuuchi M
    J Hepatol; 2012 Apr; 56(4):886-92. PubMed ID: 22173160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion.
    Duan F; Wang EQ; Lam MG; Abdelmaksoud MH; Louie JD; Hwang GL; Kothary N; Kuo WT; Hofmann LV; Sze DY
    Radiology; 2016 Feb; 278(2):612-21. PubMed ID: 26334787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future.
    Woo HY; Heo J
    Clin Mol Hepatol; 2015 Dec; 21(4):344-8. PubMed ID: 26770921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy.
    Miki I; Murata S; Uchiyama F; Yasui D; Ueda T; Sugihara F; Saito H; Yamaguchi H; Murakami R; Kawamoto C; Uchida E; Kumita SI
    World J Gastroenterol; 2017 Sep; 23(35):6437-6447. PubMed ID: 29085193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
    Deipolyi AR; Oklu R; Al-Ansari S; Zhu AX; Goyal L; Ganguli S
    J Vasc Interv Radiol; 2015 Apr; 26(4):516-22. PubMed ID: 25704226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin.
    Boulin M; Schmitt A; Delhom E; Cercueil JP; Wendremaire M; Imbs DC; Fohlen A; Panaro F; Herrero A; Denys A; Guiu B
    Eur Radiol; 2016 Feb; 26(2):601-9. PubMed ID: 26060065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
    Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
    Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superselective Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma: Rationale, Technique, and Outcome.
    Miyayama S; Matsui O
    J Vasc Interv Radiol; 2016 Sep; 27(9):1269-1278. PubMed ID: 27345337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma.
    Kim DY; Ryu HJ; Choi JY; Park JY; Lee DY; Kim BK; Kim SU; Ahn SH; Chon CY; Han KH
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1343-50. PubMed ID: 22486716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective.
    Takayasu K
    Jpn J Clin Oncol; 2012 Apr; 42(4):247-55. PubMed ID: 22407946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial chemoembolization of hepatocellular carcinoma in a rat model: the effect of additional injection of survivin siRNA to the treatment protocol.
    Vogl TJ; Oppermann E; Qian J; Imlau U; Tran A; Hamidavi Y; Korkusuz H; Bechstein WO; Nour-Eldin NE; Gruber-Rouh T; Hammerstingl R; Naguib NN
    BMC Cancer; 2016 May; 16():325. PubMed ID: 27215551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of transcatheter subsegmental and segmental arterial chemoemobolization using lipiodol for hepatocellular carcinoma.
    Takaki S; Sakaguchi H; Anai H; Tanaka T; Yamamoto K; Morimoto K; Nishiofuku H; Inoue M; Sueyoshi S; Nagata T; Hidaka T; Uchida H; Kichikawa K
    Cardiovasc Intervent Radiol; 2012 Jun; 35(3):544-54. PubMed ID: 21739345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.